Cytokine release syndrome (CRS), as known as cytokine storm syndrome, denotes a form of systemic inflammatory response syndrome characterized by a variety of chemokines such as interferons, interleukins, tumor-necrosis factors, chemokines, and other inflammatory mediators.[@bib1] Those mediators in turn are part of an innate immune response necessary for efficient clearance of infectious agents and activate more white blood cells. CRS is triggered plenty of factors involving not only infection but also medications as known as side effect of certain monoclonal antibody therapies.

In the Faqihi et al. study entitled, "Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome", we have been inquired if the development of acute respiratory failure could have been induced by a hospital acquired bacterial infection because of ARDS occurred within one week generally. Our previous article indicated that the 52-year-old woman under the diagnosis of COVID-19 developed acute respiratory failure with invasive mechanical ventilation for 15 days and the length of stay in hospital is 55 days.[@bib2] All cultures including sputum, stool, urine, blood and fungus showed negative findings. Chlamydia IgA, mycoplasma pneumonia IgM, legionellae urinary antigen, and pneumococcus antigen were negative results. No infectious possibility of hospital acquired pneumonia was confirmed. CRS grade 4 was noticed in [Table 1](#tbl1){ref-type="table"} [@bib3]. To remove cytokines, we applied 2 techniques, therapeutic plasma exchange (TPE) equipped with Granopen 030 plasmafilter and continuous veno-venous hemofiltration equipped with Pecopen 140 hemofilter, using the HF440 machine (Infomed SA, Geneva, Switzerland) for both[@bib2].Table 1Assessment at ICU admission.ParameterLevelNormal rangeParameterLevelNormal range**Haemoglobin (g/dL)**11.212.0--15.5**Creatinine (mg/dL)**0.660.5--1.2**WBC count (10ˆ3/uL)**13.33.25--9.16**Sodium (mmol/L)**138135--147**Hct (%)**32.034.8--46.3**Potassium (mmol/L)**3.43.5--5.5**Platelets (10ˆ3/uL)**281.0150--378**Interleukin-6 (pg/mL)**125\<1.8**APTT (seconds)**27.726--38**C-reactive protein (mg/dL)**8.10--0.5**PT (seconds)**10.311--13.5**LDH (U/L)**382135--225**INR**1.000.8--1.1**Albumin (g/dL)**2.93.8--5.3**ALT (U/L)**945--37**Troponin-I (ng/mL)**0.09\<0.04**AST (U/L)**1025--40**ESR (mm/hr)**692--12**Total bilirubin (mg/dL)**0.50--1.2**D-dimer (ng/mL)**7763.1\<500**Blood urea nitrogen (mg/dL)**117--20**Ferritin (ng/mL)**295.611--306**Calcium (mg/dL)**6.98.6--10.2**Lactate (mmol/L)**0.80--1.0**Phosphorus (mg/dL)**3.42.5--4.5**Fibrinogen (mg/dL)**717190--380**Vitamin D (ng/mL)**8.1\>30**Procalcitonin (ng/mL)**0.32\<0.5**Magnesium (mg/dL)**2.11.7--2.2**SARS Co--V2 (COI)**1.5\<0.26**In-hospital mortality predictionSOFA score**12High mortality**CRS grade**[a](#tbl1fna){ref-type="table-fn"}4High mortality**Possible Pathogenesis of COVID-19 related ARDSCRSAlveolar microthrombi formationTherapeutic strategy under HF440 machineTechnique 1: TPETechnique 2: CVVH**1.5 plasma x 0.065 x (1-Hct) for 3 sessionsGranopen 030 plasmafilter (LF-030-00)35 ml/kg/min for 7 daysPecopen 140 hemofilter (DF-140-00)[^1][^2][^3][^4][^5][^6]

Interestingly, the onset of COVID-19 related ARDS is different from other infectious microorganisms. When occurring acute respiratory distress syndrome (ARDS) as a result of COVID-19, Zhou and his colleagues reported median time from illness to ARDS was between 8 and 15 days.[@bib4] It recommended that 1-week onset defined by ARDS Berlin criteria was unsuitable for COVID-19-related ARDS. Therefore, we should pay more attention to the development of ARDS after one week of illness onset.

Putting understanding reason of the cytokine storm aside, more important aspects should be discussed why clinical outcomes of COVID-19 related ARDS are so unfavorable despite therapeutic strategy. Sinha addressed that COVID-19 related pneumonia produces primarily severe lung injury, without the same magnitude of systemic responses reporting in prior studies of the hyperinflammatory phenotype in ARDS.[@bib1] A recent pathologic report of patients with COVID-19 ARDS developed alveolar microthrombi which were 9 times more prevalent than found in postmortem results of patients with influenza related ARDS. Incorporating a poorly defined pathologic evidence is lack of firm pathological results may interrogate how best to manage if COVID-19 patients suffer alveolar microthrombi.[@bib1] Our patient could not be excluded thrombus formation because of very high levels of D-dimers. However, TPE could provide fresh frozen plasma replacement to improve hypercoagulable state, decrease cytokine stimulation and replaces ADAMTS13 enzyme. Kahmis and his colleague reported that COVID-19 related ARDS with TPE management had favorable clinical outcomes including extubation and 28-day mortality compared to those without TPE management (0 vs 35% mortality, p = 0.033).[@bib5] Evidence indicated that TPE may cure COVID-19 related ARDS which was induced by either cytokine storm or alveolar microthrombi. Ongoing randomized controlled trial could investigate more particular advantage of TPE on COVID-19.[@bib6]
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[^1]: Abbreviation: ALT: alanine aminotransferase; APTT: activated partial thromboplastin time; ARDS: acute respiratory distress syndrome; AST: aspartate transaminase; CRS: cytokine release syndrome; CVVH: continuous venovenous hemofiltration; Hct: hematocrit; ICU: intensive care unit; INR: international normalized ratio; SOFA: sequential organ failure assessment; PT: prothrombin time; TPE: therapeutic plasma exchange; WBC: white blood cell.

[^2]: CRS grade 1 refers to mild reaction, infusion interruption not indicated; intervention not indicated.

[^3]: CRS grade 2 refers to therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for ≤ 24 h).

[^4]: CRS grade 3 refers to prolonged (e.g., not rapidly responsive to symptomatic medication or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae (e.g., renal impairment, pulmonary infiltrates).

[^5]: CRS grade 4 refers to life-threatening consequences; vasopressor or ventilatory support indicated.

[^6]: Published CRS grading system based on[@bib3].
